Amryt Pharma plc Operating Income 2011-2026 | AMYT

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Amryt Pharma plc

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-38.6 M	-46.5 M	-50.5 M	-18 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-18 M	-50.5 M	-38.4 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
AgeX Therapeutics AGE	-9.89 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
AbCellera Biologics ABCL	-217 M	$ 3.59	-1.24 %	$ 1.07 B	Canada
ADMA Biologics ADMA	191 M	$ 15.71	-5.02 %	$ 3.74 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	-58.1 M	-	-	$ 2.17 B	USA
AlloVir ALVR	-65.4 M	-	4.14 %	$ 49.1 M	USA
Apellis Pharmaceuticals APLS	55.4 M	$ 20.29	2.17 %	$ 2.56 B	USA
Ampio Pharmaceuticals AMPE	-33.3 M	-	-11.43 %	$ 502 K	USA
ANI Pharmaceuticals ANIP	584 K	$ 75.95	-0.76 %	$ 1.47 B	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Autolus Therapeutics plc AUTL	-241 M	$ 1.5	-7.98 %	$ 383 M	Britain
Aravive ARAV	-70.8 M	-	-13.39 %	$ 1.45 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Athersys ATHX	-87.1 M	-	3.77 %	$ 22.4 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Corcept Therapeutics Incorporated CORT	44.8 M	$ 34.35	-3.74 %	$ 3.57 B	USA
AVEO Pharmaceuticals AVEO	-49.6 M	-	-	$ 521 M	USA
Corbus Pharmaceuticals Holdings CRBP	-45.1 M	$ 7.99	-5.17 %	$ 34.6 M	USA
CorMedix CRMD	-49 M	$ 6.35	-10.88 %	$ 323 M	USA
Champions Oncology CSBR	4.55 M	$ 5.79	-3.58 %	$ 79.1 M	USA
Axsome Therapeutics AXSM	-167 M	$ 160.64	-2.1 %	$ 7.99 B	USA
BridgeBio Pharma BBIO	-523 M	$ 65.51	-1.55 %	$ 12.5 B	USA
Brainstorm Cell Therapeutics BCLI	-11.7 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
Denali Therapeutics DNLI	-487 M	$ 19.73	-3.17 %	$ 3.25 B	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
Edesa Biotech EDSA	-7.01 M	$ 3.71	-13.11 %	$ 11.9 M	USA
Bellicum Pharmaceuticals BLCM	-27 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-98.1 M	-	-7.31 %	$ 87 M	USA
Equillium EQ	-14.5 M	$ 1.79	2.29 %	$ 62.2 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
BioLineRx Ltd. BLRX	-24.8 M	$ 2.75	-1.96 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	409 M	$ 60.6	0.28 %	$ 11.6 B	USA
Burford Capital Limited BUR	242 M	$ 8.26	-1.31 %	$ 1.36 B	Britain